Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARIUS trial of short-term darolutamide with radiotherapy for unfavorable intermediate-risk prostate cancer
2023-509494-23-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Biological response at 6 months. Planned start Feb 2023; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-509494-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509494-23-00.